Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment...